Physician profile
Smitha Eapen
NPI 1114303195
$446.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.50 | 2021-2022 | |
| Myovant Sciences INC. | $65.28 | 2021-2022 | |
| Janssen Biotech, INC. | $64.99 | 2021 | |
| Genentech USA, INC. | $64.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.40 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $20.35 | 2022 | |
| Amgen INC. | $19.98 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.24 | 2021 | |
| Array Biopharma INC | $16.01 | 2021 | |
| Lilly USA, LLC | $15.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.